Moderate Plaque psoriasis

DrugDrug NameDrug Description
DB12917BimekizumabAn anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
DB11776BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB01013Clobetasol propionateA corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis.
DB16650DeucravacitinibA TYK2 inhibitor being investigated as a treatment for psoriasis.
DB00005EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
DB11834GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB09029SecukinumabAn immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
DB05679UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
DrugDrug NameTargetType
DB12917BimekizumabInterleukin-17Atarget
DB12917BimekizumabInterleukin-17Ftarget
DB01013Clobetasol propionateGlucocorticoid receptortarget
DB01013Clobetasol propionateCytochrome P450 3A4enzyme
DB01013Clobetasol propionateCytochrome P450 3A5enzyme
DB01013Clobetasol propionateAnnexin A1target
DB01013Clobetasol propionateMineralocorticoid receptortarget
DB01013Clobetasol propionateCorticosteroid-binding globulincarrier
DB01013Clobetasol propionateSerum albumincarrier
DB16650DeucravacitinibNon-receptor tyrosine-protein kinase TYK2target
DB16650DeucravacitinibCytochrome P450 1A2enzyme
DB16650DeucravacitinibCytochrome P450 2B6enzyme
DB16650DeucravacitinibCytochrome P450 2D6enzyme
DB16650DeucravacitinibCocaine esteraseenzyme
DB16650DeucravacitinibUDP-glucuronosyltransferase 1-9enzyme
DB16650DeucravacitinibP-glycoprotein 1transporter
DB16650DeucravacitinibATP-binding cassette sub-family G member 2transporter
DB16650DeucravacitinibSolute carrier family 22 member 1transporter
DB16650DeucravacitinibSolute carrier organic anion transporter family member 1B3transporter
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptComplement component 1q (C1q)target
DB11834GuselkumabInterleukin-23 subunit alphatarget
DB09029SecukinumabInterleukin-17Atarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DrugDrug NamePhaseStatusCount
DB11834Guselkumab3Recruiting1